PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
Titel:
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
Auteur:
Moskowitz, Alison J Schöder, Heiko Yahalom, Joachim McCall, Susan J Fox, Stephanie Y Gerecitano, John Grewal, Ravinder Hamlin, Paul A Horwitz, Steven Kobos, Rachel Kumar, Anita Matasar, Matthew Noy, Ariela Palomba, M Lia Perales, Miguel-Angel Portlock, Carol S Sauter, Craig Shukla, Neerav Steinherz, Peter Straus, David Trippett, Tanya Younes, Anas Zelenetz, Andrew Moskowitz, Craig H